Dr Kouladjian O'Donnell is a Lecturer, teaching & research, at the School of Pharmacy, Faculty of Medicine and Health, The University of Sydney. She also conducts research based at the Kolling Institute, Royal North shore Hospital, and is a registered credentialled pharmacist who provides Home Medicine Review services for older Australians. Dr Kouladjian O’Donnell has led the development of digital tools that can be translated into clinical practice to address polypharmacy-related issues, including The Drug Burden Index Calculator© and the Goal-directed Medication review Electronic Decision Support System (G-MEDSS) ©. These tools are designed to guide healthcare practitioners to deprescribe inappropriately prescribed anticholinergic and sedative medications, while considering their patient's goals of care. Her research is featured in national guiding principles for medication management.

Eileen is a Lived Experience Consultant and Research Partner with the Mental Health Australia General Clinical Trials Network (MAGNET) and Deputy Chair of the MAGNET Lived Experience Research Partners (LERP) Platform Committee. She has over 35 years demonstrated expertise and leadership in Australia and internationally in community, educational and clinical sectors, including disability, health and mental health services, collaborative research, policy and humanitarian projects. Her qualifications include M Couns. Grad Dip DMT (Reg DTAA), BA Communications, CertIV TAE, CertIV MHPW & Cert Supervision. Eileen is dedicated to transformative community outcomes, through embedding the diversity of lived experience consumer and family, friends and kin carer leadership within authentic engagement in all aspects of governance, policy, training, workforce and research.

Linda Truong is an Australian neuropharmacologist and research neurology clinical trials specialist in academia, public health hospitals, and global industry, attesting to the quality of her research ideas and the ability to prosecute international clinical trials over the past two decades. Linda was appointed clinical trial manager (2016), clinical trials researcher (2020), and then senior clinical trial manager (2022), at NSW Health and a NHMRC Centre for Research Excellence, and now Executive Director (Strategic Partnerships) at HAIKDA Research (2023). Linda has successfully collaborated extensively with both Australian and international clinical researchers and industry partners, addressing critical scientific inquiries related to clinical trial design, cannabis-based therapies, neurological disorders such as epilepsy, and innovative methodologies for co-designing clinical trials in neurodegenerative diseases alongside patient and consumer groups. As a national leader in clinical trials, her research has directly influenced clinical practice by providing the evidence base to understand the use of new epilepsy medications in four large paediatric hospitals in NSW, clarifying the safety and efficacy data of the new drug on seizures and facilitating the approval of new medicines for approval by the TGA. Linda has brought together and worked with clinical leaders, senior neuroscientists, clinical pharmacologists, and NSW health allied health professionals and developed the resources/infrastructure needed to address fundamental questions of importance to a group of epilepsy disorders of major health significance. These have revealed details of prescribing guidelines, transition pathways, new models of care, and informed clinical trial method modelling for therapeutic development and drug delivery for rare diseases. To facilitate further research discovery, Linda has made these resources and knowledge available to Australian researchers for further transformative research studies in her role on independent ethics, scientific and data monitoring committees (2018). Linda has been awarded a research grant and scholarship to support her research in Newcastle, Australia, and is one of the principal investigators on a research project to co-design new methodologies for the design of clinical trials with the participation of rare disease patient consumer groups. In clinical trials, registered drugs are tested in children and adults in NSW and have formed the basis for the first patient-centred clinical trial for epilepsy, with recent work targeting cannabis-based medicines. Linda serves as a passionate advocate for neurological spinal cord injury and works with numerous patient consumer groups for rare disease to incorporate the patient voice in the promotion of national patient-centred clinical trials for rare epilepsy.